Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 3
2003 6
2004 5
2005 12
2006 15
2007 43
2008 52
2009 78
2010 74
2011 57
2012 89
2013 108
2014 108
2015 109
2016 88
2017 75
2018 92
2019 64
2020 7
Text availability
Article attribute
Article type
Publication date

Search Results

976 results
Results by year
Filters applied: . Clear all
Page 1
Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G.
Shitara K, Yonesaka K, Denda T, Yamazaki K, Moriwaki T, Tsuda M, Takano T, Okuda H, Nishina T, Sakai K, Nishio K, Tokunaga S, Yamanaka T, Boku N, Hyodo I, Muro K. Shitara K, et al. Cancer Sci. 2016 Dec;107(12):1843-1850. doi: 10.1111/cas.13098. Cancer Sci. 2016. PMID: 27712015 Free PMC article. Clinical Trial.
Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer.
Takaoka T, Kimura T, Shimoyama R, Kawamoto S, Sakamoto K, Goda F, Miyamoto H, Negoro Y, Tsuji A, Yoshizaki K, Goji T, Kitamura S, Yano H, Okamoto K, Kimura M, Okahisa T, Muguruma N, Niitsu Y, Takayama T. Takaoka T, et al. Cancer Chemother Pharmacol. 2016 Aug;78(2):397-403. doi: 10.1007/s00280-016-3096-5. Epub 2016 Jun 24. Cancer Chemother Pharmacol. 2016. PMID: 27342247 Clinical Trial.
Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.
Price T, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Thomas A, Tjulandin S, Guan X, Peeters M. Price T, et al. Eur J Cancer. 2016 Nov;68:51-59. doi: 10.1016/j.ejca.2016.08.010. Epub 2016 Oct 5. Eur J Cancer. 2016. PMID: 27716478 Free article. Clinical Trial.
Panitumumab in the treatment of colon cancer: A biomarker dilemma.
Scott A, Messersmith WA, Jimeno A, Davies SL. Scott A, et al. Drugs Today (Barc). 2014 Oct;50(10):679-90. doi: 10.1358/dot.2014.50.10.2221787. Drugs Today (Barc). 2014. PMID: 25374966 Review.
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.
Pietrantonio F, Petrelli F, Coinu A, Di Bartolomeo M, Borgonovo K, Maggi C, Cabiddu M, Iacovelli R, Bossi I, Lonati V, Ghilardi M, de Braud F, Barni S. Pietrantonio F, et al. Eur J Cancer. 2015 Mar;51(5):587-94. doi: 10.1016/j.ejca.2015.01.054. Epub 2015 Feb 9. Eur J Cancer. 2015. PMID: 25673558 Review.
Panitumumab for the treatment of metastatic colorectal cancer: a review.
Del Prete M, Giampieri R, Faloppi L, Bianconi M, Bittoni A, Andrikou K, Cascinu S. Del Prete M, et al. Immunotherapy. 2015;7(7):721-38. doi: 10.2217/imt.15.46. Epub 2015 Aug 7. Immunotherapy. 2015. PMID: 26250414 Review.
Mechanisms of resistance to anti-EGFR therapy in colorectal cancer.
Zhao B, Wang L, Qiu H, Zhang M, Sun L, Peng P, Yu Q, Yuan X. Zhao B, et al. Oncotarget. 2017 Jan 17;8(3):3980-4000. doi: 10.18632/oncotarget.14012. Oncotarget. 2017. PMID: 28002810 Free PMC article. Review.
976 results
Jump to page
Feedback